Celularity (CELU) Registration Filing summary

Company overview and business model

• Focuses on regenerative and cellular medicines targeting aging-related and degenerative diseases, with commercial biomaterial products and a pipeline of placental-derived allogeneic cell therapies for indications such as diabetic foot ulcer and Crohn's disease.

• Operates three business segments: Cell Therapy (R&D stage), Degenerative Disease (commercial biomaterials), and BioBanking (stem cell storage services).

• Commercial products include Biovance 3L, Rebound, Interfyl, and CentaFlex, with distribution partnerships in the U.S. and Asia.

• Leverages a proprietary manufacturing platform (Celularity IMPACT) and a 147,215 sq. ft. GMP facility for integrated R&D and production.

Financial performance and metrics

• For the nine months ended September 30, 2024: net revenues were $36.1 million (up 239% YoY), with $32 million from Degenerative Disease (biomaterials) and gross margins of 79%.

• Net loss for the same period was $44.6 million; accumulated deficit reached $886.4 million as of September 30, 2024.

• Cash and cash equivalents were $0.1 million as of September 30, 2024, with $46.1 million in debt, all due within one year.

• Goodwill and IPR&D impairments in 2023 totaled $220.1 million due to discontinued cell therapy programs.

Use of proceeds and capital allocation

• Net proceeds of approximately $8.7 million (or $10.1 million if over-allotment is exercised) expected, based on an assumed offering price of $2.16 per share.

• Proceeds will be used for redemption of convertible promissory notes (~$2.1 million), payment of cash interest on senior secured debt (~$2.1 million), and working capital/general corporate purposes.

• A portion of proceeds is allocated to pay accrued interest on loans to RWI and Starr as part of loan maturity extensions.